Brief: Nw bio confirms phase III trial of DCVax-L for GBM brain cancer is ongoing

Northwest Biotherapeutics

21/08/2015 20:23

Aug 21 (Reuters) - Northwest Biotherapeutics Inc  NWBO.O : 
 * Nw bio confirms phase III trial of DCVax-L for GBM brain cancer is ongoing 
 * Says over 300 patients have been recruited for the trial. the total 
   anticipated enrollment is 348 patients 
 * Only change in status of trial is that new screening of patient candidates 
   for the trial has been temporarily suspended 
 * Says patients in trial continuing to be treated per protocol, including in 
   Germany 
 * New screening of patient for trial temporarily suspended while it submits 
   some info from the trial for regulatory review 
 * Says company has sought to have the eudract listing corrected 
 * Is in process of preparing trial information for regulatory review and 
   anticipates submission within next couple of weeks 
 * Says anticipates submission of trial information within the next couple of 
   weeks 
 * Trial status in Germany is that the trial is ongoing ,co has only undertaken 
   temporary suspension of new screening 
 
* Source text for Eikon  ID:nPn73ZqZR  
 
* Further company coverage  NWBO.O  ((Bengaluru Newsroom; +1 646 223 8780))